Mirror Biologics, Inc., specializing in development and manufacturing of immunotherapy products where the active ingredient ...

An Institute for Value-Based Medicine regional event in Houston, Texas, covered inconsistencies with the integration of precision medicine in oncology practices, the evolution of treatment for ...

A TRANSPLANT recipient has died of cancer after contracting the illness from his organ donor. The unnamed patient, 69, from Arizona underwent an organ transplant to treat his liver ...

CytoMed Therapeutics has signed a business and research collaboration agreement with SunAct Cancer Institute for a clinical trial in India.

The Phase 1a/b trial of ADRX-0405 is taking place at trial sites across the U.S., with first readouts expected in Q4 2025.

In the post, Johnson also discussed precautions for surviving in polluted environments, emphasizing the importance of ...

The one-and-a-half-day symposium provides an overview of recent advances in the treatment of solid tumors with novel targeted agents and treatment combinations, as well as evolving molecular-based ...

Simcere Zaiming Pharmaceutical Co. Ltd. has announced clinical trial approvals in China and the U.S. for its CDH6-targeting antibody-drug conjugate (ADC), SIM-0505, for advanced solid tumors. A global ...

More than two years after acquiring Tarus Therapeutics, Portage Biotech is relaunching Tarus’ adenosine receptor antagonists ...

PD-1 x VEGF antibodies show potential to surpass checkpoint inhibitors as standard-of-care in multiple oncology indications • ...

Immunotherapy has revolutionized the treatment landscape for solid tumors, achieving remarkable success in some patients while others show variable ...

The FDA approved subcutaneous nivolumab for solid tumors, tiselizumab for advanced gastric and GEJ cancers, and key 2024 breast cancer breakthroughs are reviewed. Experts provide perspective on ...